116 related articles for article (PubMed ID: 22570265)
1. Bayesian estimation of pharmacokinetic parameters of vancomycin in patients with decreasing renal function.
Yamamoto T; Terakawa H; Hisaka A; Suzuki H
J Pharm Sci; 2012 Aug; 101(8):2968-75. PubMed ID: 22570265
[TBL] [Abstract][Full Text] [Related]
2. Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods.
Tsuji Y; Hiraki Y; Mizoguchi A; Sadoh S; Sonemoto E; Kamimura H; Karube Y
J Clin Pharm Ther; 2009 Aug; 34(4):465-72. PubMed ID: 19583680
[TBL] [Abstract][Full Text] [Related]
3. Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin.
Hirai K; Ishii H; Shimoshikiryo T; Shimomura T; Tsuji D; Inoue K; Kadoiri T; Itoh K
Ther Drug Monit; 2016 Dec; 38(6):706-710. PubMed ID: 27681114
[TBL] [Abstract][Full Text] [Related]
4. [Bayesian forecasting of plasma vancomycin concentration using time-dependent pharmacokinetics].
Nakamura T; Wakaki N; Kimura Y; Goto N; Masada M
Yakugaku Zasshi; 1996 Nov; 116(11):876-83. PubMed ID: 8981831
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Bayesian predictability of vancomycin concentration in patients with various degrees of renal function.
Ohnishi A; Yano Y; Shimamura K; Oguma T
Biol Pharm Bull; 2001 Dec; 24(12):1446-50. PubMed ID: 11767122
[TBL] [Abstract][Full Text] [Related]
6. Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy.
Oda K; Jono H; Kamohara H; Nishi K; Tanoue N; Saito H
Pharm Res; 2020 May; 37(6):108. PubMed ID: 32468340
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters.
Teramachi H; Hatakeyama H; Matsushita R; Imai Y; Miyamoto K; Tsuji A
Biol Pharm Bull; 2002 Oct; 25(10):1333-8. PubMed ID: 12392090
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the prediction accuracy of vancomycin concentrations determined by patient-specific parameters as estimated by Bayesian analysis.
Hiraki Y; Onga T; Mizoguchi A; Tsuji Y
J Clin Pharm Ther; 2010 Oct; 35(5):527-32. PubMed ID: 20831677
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic parameters of vancomycin in critically ill patients.
Llopis-Salvia P; Jiménez-Torres NV
J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment.
Hirai T; Hanada K; Kanno A; Akashi M; Itoh T
Eur J Clin Pharmacol; 2019 Jun; 75(6):859-866. PubMed ID: 30770940
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens.
Lin WW; Wu W; Jiao Z; Lin RF; Jiang CZ; Huang PF; Liu YW; Wang CL
Eur J Clin Pharmacol; 2016 Jan; 72(1):29-37. PubMed ID: 26423622
[TBL] [Abstract][Full Text] [Related]
12. Influence of cerebral fluid drainage on the pharmacokinetics of vancomycin in neurosurgical patients.
Ichie T; Urano K; Suzuki D; Okada T; Kobayashi N; Hayashi H; Sugiura Y; Yamamura K; Sugiyama T
Pharmazie; 2015 Jun; 70(6):404-9. PubMed ID: 26189303
[TBL] [Abstract][Full Text] [Related]
13. Duration of Systemic Inflammatory Response Syndrome Influences Serum Vancomycin Concentration in Patients With Sepsis.
Chuma M; Makishima M; Imai T; Tochikura N; Sakaue T; Kikuchi N; Kinoshita K; Kaburaki M; Yoshida Y
Clin Ther; 2016 Dec; 38(12):2598-2609. PubMed ID: 27836495
[TBL] [Abstract][Full Text] [Related]
14. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model.
Cetin H; Olgar S; Oktem F; Ciris M; Uz E; Aslan C; Ozguner F
Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1181-5. PubMed ID: 17880374
[TBL] [Abstract][Full Text] [Related]
15. Effect of cilastatin on renal handling of vancomycin in rats.
Kusama M; Yamamoto K; Yamada H; Kotaki H; Sato H; Iga T
J Pharm Sci; 1998 Sep; 87(9):1173-6. PubMed ID: 9724573
[TBL] [Abstract][Full Text] [Related]
16. Role of the poly(ADP-ribose)polymerase activity in vancomycin-induced renal injury.
Dalaklioglu S; Tekcan M; Gungor NE; Celik-Ozenci C; Aksoy NH; Baykal A; Tasatargil A
Toxicol Lett; 2010 Feb; 192(2):91-6. PubMed ID: 19833176
[TBL] [Abstract][Full Text] [Related]
17. Decreased renal accumulation and toxicity of a new VCM formulation in rats with chronic renal failure.
Hodoshima N; Masuda S; Inui K
Drug Metab Pharmacokinet; 2007 Dec; 22(6):419-27. PubMed ID: 18159129
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies].
Sadoh S; Tsuji Y; Tsukamoto K
Yakugaku Zasshi; 2010 Jan; 130(1):69-73. PubMed ID: 20046068
[TBL] [Abstract][Full Text] [Related]
19. Interaction between levofloxacin and vancomycin in rats--study of serum and organ levels.
Mori H; Nakajima T; Nakayama A; Yamori M; Izushi F; Gomita Y
Chemotherapy; 1998; 44(3):181-9. PubMed ID: 9612608
[TBL] [Abstract][Full Text] [Related]
20. Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance.
Yu YX; Lu J; Lu HD; Li L; Li JJ; Shi L; Duan LF; Zhuang ZW; Xue SD; Shen Y; Tang L
Eur J Hosp Pharm; 2022 Mar; 29(e1):e6-e14. PubMed ID: 33414258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
